Summing up
While it is always sensible to look at a company’s total liabilities, it is very reassuring that Pharma Mar has €168.7m in net cash. And it impressed us with free cash flow of €253m, being 227% of its EBIT.
So is Pharma Mar’s debt a risk? It doesn’t seem so to us. When analysing debt levels, the balance sheet is the obvious place to start. However, not all investment risk resides within the balance sheet – far from it. Case in point: We’ve spotted 3 warning signs for Pharma Mar you should be aware of, and 1 of them is a bit unpleasant. ...
